<%%first name%%>
As it usually takes three-to-four years to prepare for large-scale manufacturing capacity, biopharma organizations are faced with decisions on how much drug to produce long before Phase III trials are even completed. With so many unknowns, it is difficult for developers to realistically forecast demand this early. Instead of trying to improve forecasting or erring on the side of overcapacity, biopharma needs a better solution.
Read the latest whitepaper on how flexibility through single-use solutions such as multiplexing can help biopharmas mitigate the risks of inaccurate forecasting in biomanufacturing.
Download: Multiplexing: Managing Risk With Proven, Single-Use Solutions |
